Minireviews
Copyright ©The Author(s) 2024.
World J Gastrointest Oncol. Jul 15, 2024; 16(7): 2915-2924
Published online Jul 15, 2024. doi: 10.4251/wjgo.v16.i7.2915
Figure 4
Figure 4 Imatinib combined with anti-programmed death receptor-1/programmed death ligand-1 therapy can inhibit M2 polarization of tumor-associated macrophages. IDO: 2,3-dioxygenase; IFN: Interferon; IL: Interleukin; PD-1/PD-L1: Programmed death receptor-1/programmed death ligand-1; TGF: Transforming growth factor; TNF: Tumor necrosis factor.